INTER-LOCAL: International Funding Call for Local Treatment Strategies in Rare and Hard-to-Treat Cancers

Eligibility & scope

Supports late-phase (phase 2/3) international clinical trials focused on radiotherapy or surgery as core experimental interventions for rare cancers (incidence <6/100,000/year) and/or hard-to-treat cancers (5-year survival <25%). Proposals must include partners from at least 3 of the 5 funding countries and demonstrate strong rationale for international collaboration, patient involvement, and quality-of-life assessment.